| Literature DB >> 34883601 |
Jinbao Liu1, Shuang Yu2, Wanying Qu2, Zheng Jin1,3, Kai Zhao2,3.
Abstract
Herein, a novel chitosan derivative nanoparticle was proposed to function as a delivery carrier. First of all, an improvement was made to the way N-2-hydroxypropyl trimcthyl ammonium chloride chitosan (N-2-HACC) was synthesized. Moreover, the solution to one-step synthesis of N-2-HACC from chitosan (CS) was developed. Different from the previous report, the synthesis process was simplified, and there was a reduction in the amount of 2,3-epoxypropyl trimethyl ammonium chloride (EPTAC) used. With its excellent water solubility maintained, the relatively low degree of substitution was controlled to facilitate the cross-linking reaction. The results obtained from 1H-NMR, FTIR spectroscopy, and XRD indicated a smooth EPTAC onto CS for the formation of N-2-HACC with 59.33% the degree of substitution (DS). According to our results, N-2-HACC could be dissolved in various organic solvents, deionized water, 1% acetic acid aqueous solution, and others at room temperature. Finally, a novel chitosan nanoparticle material was prepared using the self-assembly method with β-glycerophosphate sodium (β-GC), with excellent immune properties achieved, thus providing a new strategy for chitosan self-assembled nanoparticles.Entities:
Keywords: N-2-HACC; nanoparticle; quaternized chitosan derivative; self-assembly
Year: 2021 PMID: 34883601 PMCID: PMC8659217 DOI: 10.3390/polym13234097
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1The schemes of synthesis of materials. (a) N-2-HACC; (b) N-2-HACC/PEDV NPs.
The vaccine composition with different adjuvant doses.
| Group | N-2-HACC NPs (%, | PEDV (mL) | N-2-HACC NPs (g/mL) | Adjuvant Dose (mL) |
|---|---|---|---|---|
| 1 | 0.5 | 1 | 0.01 | 1 |
| 2 | 1 | 1 | 0.02 | 1 |
| 3 | 5 | 1 | 0.1 | 1 |
| 4 | 10 | 1 | 0.2 | 1 |
Figure 2FTIR spectra of CS and N-2-HACC.
Figure 31H-NMR spectra of CS and N-2-HACC.
Figure 4XRD of CS and N-2-HACC.
Figure 5The typical conductometric titration curves of N-2-HACC.
Experimental data of CS.
| t (s) |
| ln | ln |
|
| |
|---|---|---|---|---|---|---|
| - | 92 | - | - | - | - | - |
| 6 | 474 | 5.1522 | 1.6394 | 0.2732 | 4.1522 | 0.6920 |
| 4 | 364 | 3.9565 | 1.3754 | 0.3438 | 2.9565 | 0.7391 |
| 2.4 | 204 | 2.2174 | 0.7963 | 0.3318 | 1.2174 | 0.5073 |
| 1.71 | 166 | 1.8043 | 0.5902 | 0.3451 | 0.8043 | 0.4704 |
| 1.33 | 147 | 1.5978 | 0.4686 | 0.3524 | 0.5978 | 0.4495 |
Figure 6The relationship between C-lnη and C-η of CS. T = 25.15 ± 0.5 °C.
Experimental data of N-2-HACC.
| t (s) |
| ln | ln |
|
| |
|---|---|---|---|---|---|---|
| - | 92 | - | - | - | - | - |
| 5 | 178 | 1.9348 | 0.6600 | 0.1320 | 0.9348 | 0.1870 |
| 3.33 | 146.3 | 1.5092 | 0.4639 | 0.1393 | 0.5902 | 0.1773 |
| 2 | 123 | 13370 | 0.2904 | 0.1452 | 0.3370 | 0.1685 |
| 1.43 | 114 | 1.2391 | 0.2144 | 0.1499 | 0.2391 | 0.1672 |
| 1.1 | 108 | 1.1739 | 0.1603 | 0.1458 | 0.1739 | 0.1581 |
Figure 7The relationship between C-lnη and C-η of N-2-HACC. T = 25.15 ± 0.5 °C.
Figure 8The curve of conductivity of solution with volume of AgNO3.
Solubility of CS and N-2-HACC in different solvents at room temperature.
| Sample Solvent | CS | N-2-HACC |
|---|---|---|
| Solubility (mg/mL) | ||
| Normal saline, 0.9% ( | - | 63.9 ± 0.71 |
| Isopropyl alcohol | - | - |
| Deionized water | - | 73 ± 1.41 |
| Acetic acid, 1% ( | 35.1 ± 2.12 | 188.9 ± 4.95 |
| Sodium hydroxide, 1% ( | - | 54.1 ± 0.99 |
“-” means insoluble.
Figure 9TEM morphology of N-2-HACC NPs.
Figure 10Zeta potential and size distribution of N-2-HACC NPs.
Figure 11ELISA antibody dynamics regularity of serum in guinea pigs.